{"id":842628,"date":"2026-10-20T18:01:03","date_gmt":"2026-10-20T18:01:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=842628"},"modified":"2026-10-20T18:01:03","modified_gmt":"2026-10-20T18:01:03","slug":"intratumoral-cancer-therapies-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20252034-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/intratumoral-cancer-therapies-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20252034-delveinsight_842628.html","title":{"rendered":"Intratumoral Cancer Therapies Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2025-2034 | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1792439333.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Intratumoral Cancer Therapies Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2025-2034 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1792439333.jpg\" alt=\"Intratumoral Cancer Therapies Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2025-2034 | DelveInsight\" width=\"225\" height=\"95\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Key Intratumoral Cancer Therapies Companies in the market include \u2013 Nanobiotix, Replimune, Sirnaomics, OncoSec Medical, Daiichi Sankyo, Amgen, Merck &#038; Co (Viralytics), Moderna Therapeutics, Idera Pharmaceuticals, Philogen, Lokon Pharma, Hookipa Biotech, Vyriad, Intensity Therapeutics, and others.<\/div>\n<p style=\"text-align: justify;\">(Albany, US), October 20, 2026 &#8211; DelveInsight&#8217;s &#8216;Intratumoral Cancer Therapies Treatment Market Insight, Epidemiology and Market Forecast &ndash; 2034&#8217; report delivers an in-depth understanding of Intratumoral Cancer Therapies, the historical and competitive landscape, as well as the Intratumoral Cancer Therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">Explore the intricate details of the Intratumoral Cancer Therapies Market Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Intratumoral Cancer Therapies Treatment Market<\/a><\/p>\n<p style=\"text-align: justify;\">Key Takeaways from the Intratumoral Cancer Therapies Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Intratumoral Cancer Therapies market in the 7MM was valued at approximately USD 115 million in 2025.<\/p>\n<\/li>\n<li>\n<p>The Intratumoral Cancer Therapies market is projected to grow at a CAGR of 49.10%, reaching USD 4,193 million by 2034 in leading countries (US, EU4, UK, and Japan).<\/p>\n<\/li>\n<li>\n<p>The United States is the largest Intratumoral Cancer Therapies market and accounts for approximately 80% of the market share.<\/p>\n<\/li>\n<li>\n<p>Among the selected indications for intratumoral therapies, non-melanoma accounted for the highest number of cases across the 7MM and is anticipated to increase at ~2.0% in the coming decade.<\/p>\n<\/li>\n<li>\n<p>Currently, only IMLYGIC is approved by the US FDA for melanoma treatment and garnered more than 90% of the total intratumoral therapies market.<\/p>\n<\/li>\n<li>\n<p>Various intratumoral therapy approaches, including immune-potentiating cytokines, TLR and STING agonists, T-cell checkpoint inhibitors, suppressive cytokine inhibitors or traps, OVs, and plasmid DNA, are in clinical development for melanoma patients.<\/p>\n<\/li>\n<li>\n<p>Among the emerging Intratumoral Cancer Therapies, OncoSec Medical&#8217;s TAVO (tavokinogene telseplasmid), a plasmid-based Interleukin-12, is expected to generate the highest revenue.<\/p>\n<\/li>\n<li>\n<p>The leading Intratumoral Cancer Therapies Companies include Nanobiotix, Replimune, Sirnaomics, OncoSec Medical, Daiichi Sankyo, Amgen, Merck &amp; Co (Viralytics), Moderna Therapeutics, Idera Pharmaceuticals, Philogen, Lokon Pharma, Hookipa Biotech, Vyriad, Intensity Therapeutics, and others.<\/p>\n<\/li>\n<li>\n<p>Promising Intratumoral Cancer Therapies include HENSIFY (NBTXR3), STP705 (cotsiranib), Vidutolimod + nivolumab, LTX-315, AIV001, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Get a Free sample for the Intratumoral Cancer Therapies Market Forecast, Size &amp; Share Analysis Report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Intratumoral Cancer Therapies Therapeutics Market<\/a><\/p>\n<p style=\"text-align: justify;\">Intratumoral Cancer Therapies Overview<\/p>\n<p style=\"text-align: justify;\">Cancer is a broad term for diseases caused by abnormal cells quickly dividing and spreading to other tissues and organs, and it is one of the world&#8217;s major causes of death. Intratumoral therapy is a promising treatment option for several cancer types. Intratumoral immunotherapy is a revolutionary cancer treatment that uses sophisticated antibodies directly injected into the cancer tumors instead of through a vein (intravenously). These therapies aim to deliver immunostimulatory products directly into a tumor lesion (primary or metastatic) to prime and\/or boost an antitumor immune response. Intratumoral therapy aims to generate a systemic immune response against the tumor upon local immune stimulation due to the circulation in the blood and lymph of immune cells and antibodies. Therefore, the objective of such a therapeutic strategy is to use the tumor as its vaccine and generate a polyclonal adaptive immune response mediated by T and\/or B cells against pre-existing tumor-specific antigens (TSA) or tumor-associated antigens (TAA). Intratumoral therapies are delivered directly into tumors, targeting cancer cells locally, often with minimal impact on surrounding healthy tissue.<\/p>\n<p style=\"text-align: justify;\">Intratumoral Cancer Therapies Market Size and Forecast<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>2025 Intratumoral Cancer Therapies Market Size: USD 115 million<\/p>\n<\/li>\n<li>\n<p>2034 Projected Intratumoral Cancer Therapies Market Size: USD 4,193 million<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Growth Rate (2025-2034): 49.10% CAGR<\/p>\n<\/li>\n<li>\n<p>Largest Intratumoral Cancer Therapies Market: United States<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Intratumoral Cancer Therapies Market Segmentation in the 7MM<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Intratumoral Cancer Therapies Market Size<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Market Size by Therapies<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Market Size by Class<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Download the report to understand which factors are driving Intratumoral Cancer Therapies market trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Intratumoral Cancer Therapies Market Size<\/a><\/p>\n<p style=\"text-align: justify;\">Intratumoral Cancer Therapies Epidemiology Key Findings<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Among the selected indications for intratumoral therapies, non-melanoma accounted for the highest number of cases across the 7MM and is anticipated to increase at ~2.0% in the coming decade.<\/p>\n<\/li>\n<li>\n<p>In the US, breast cancer constitutes approximately 30% of cancer cases, with the Intratumoral Cancer Therapies incidence rate steadily increasing.<\/p>\n<\/li>\n<li>\n<p>Rising incidence of cancers eligible for intratumoral therapies highlights the expanding patient pool and the demand for novel, localized cancer treatments.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Approved Therapies for Intratumoral Cancer Therapies<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>IMLYGIC (talimogene laherparepvec): Amgen<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">IMLYGIC (T-VEC) by Amgen, the first oncolytic virus, was approved by the US FDA in 2015 for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after the initial surgery. In December 2015, the European Commission (EC) also approved it for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC, and IVM1a), with no bone, brain, lung, or other visceral diseases. It is a genetically modified herpes simplex virus type 1 designed to replicate within tumors and produce an immunostimulatory protein called granulocyte-macrophage colony-stimulating factor (GM-CSF).<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DELYTACT (G47&Delta;): Daiichi Sankyo<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">DELYTACT is a triple-mutated, replication-conditional herpes simplex virus type 1 (HSV-1) that has been developed to replicate only in cancer cells. In 2021, it received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for a duration of 7 years, to be commercialized only at hospitals (served as trial sites) for the treatment of patients with malignant glioma. Approval was based on data from a single-arm Phase II trial, which showed that DELYTACT improved chances of survival at one year in patients with residual or recurrent glioblastoma previously treated with radiotherapy and temozolomide chemotherapy. It is the first oncolytic virus therapy to be launched anywhere in the world for brain cancer, and only the third oncolytic virus therapy to be made available to patients worldwide.<\/p>\n<p style=\"text-align: justify;\">Intratumoral Cancer Therapies Pipeline Analysis<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>HENSIFY (NBTXR3): Nanobiotix<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">HENSIFY, a first-in-class product, introduces a new, physical mechanism of action. It was designed by Nanobiotix to physically destroy tumors and activate the immune system for local control and systemic disease treatment when combined with radiation therapy. It is an aqueous suspension of crystalline hafnium oxide (HfO2) nanoparticles designed for injection directly into a tumor before a patient&#8217;s first standard radiotherapy treatment. When exposed to ionizing radiation, HENSIFY amplifies the localized, intratumor killing effect of that radiation, while the dose passing through healthy tissues remains unchanged. In February 2020, Nanobiotix announced that the US FDA had granted FTD for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for treating patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy. It is currently in Phase III of clinical development for the treatment of locally advanced head and neck squamous cell carcinoma, and NBTXR3 is also under evaluation in other indications such as lung, head, neck, liver, and prostate cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>STP705 (cotsiranib): Sirnaomics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">STP705 is Sirnaomics&#8217; leading product candidate, a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-&beta;1 and COX-2 gene expression directly. The drug is composed of two siRNA oligonucleotides targeting TGF-&beta;1 and COX-2 mRNA, respectively, and formulated in nanoparticles with a proprietary histidine-lysine co-polymer (HKP) peptide. Three product pipeline programs are currently prioritized for STP705: late-stage clinical development for Squamous Cell Carcinoma in situ (isSCC), completion of Phase II for Basal Cell Carcinoma (BCC), and Phase I for fat remodeling. STP705 has also received an Orphan Drug Designation for the treatment of cholangiocarcinoma (CCA) and primary sclerosing cholangitis (PSC).<\/p>\n<p style=\"text-align: justify;\">Discover more about therapies set to grab Major Intratumoral Cancer Therapies Market Share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Intratumoral Cancer Therapies Market Drivers and Barriers<\/a><\/p>\n<p style=\"text-align: justify;\">Intratumoral Cancer Therapies Market Outlook<\/p>\n<p style=\"text-align: justify;\">The Intratumoral Cancer Therapies market outlook is expected to grow significantly in the coming years, owing to the increasing number of patients being diagnosed with cancer, the growing awareness regarding these therapies, and the increasing number of intratumoral cancer therapies under investigation. To date, approved intratumoral cancer therapies include IMLYGIC (talimogene laherparepvec) and DELYTACT (G47&Delta;), which is approved only in Japan. Currently, IMLYGIC is dominating the market; however, vidutolimod and RP1 are likely to have a substantial impact on the intratumoral market landscape in the coming decade. Several companies, including Nanobiotix, Sirnaomics, Replimune, and others, are developing intratumoral cancer therapies for various indications. At present, melanoma garnered the highest revenue among the selected cancer indications, while in the upcoming years, intratumoral cancer therapies are likely to be considered a promising therapy for non-melanoma skin cancer. The United States accounts for approximately 80% of the Intratumoral Cancer Therapies market share. Among EU4 and the UK, Germany accounted for the highest market share, followed by France, whereas Spain accounted for the lowest market.<\/p>\n<p style=\"text-align: justify;\">Intratumoral Cancer Therapies Treatment Landscape<\/p>\n<p style=\"text-align: justify;\">The Intratumoral Cancer Therapies treatment landscape has rapidly evolved, with several promising advancements in recent years. The first successful intratumoral immunotherapy was observed at the end of the 19th century following intratumoral injections of pro-inflammatory bacterial extracts. In 2015, with the approval of T-Vec, an oncolytic virus to treat melanoma, interest increased, and several companies are now developing intratumoral drugs. Intratumoral therapy has several advantages over existing treatments, e.g., it causes fewer side effects. Companies like Nanobiotix, Replimune, and Sirnaomics have redirected their efforts toward advancing their intratumoral cancer therapies clinical development programs, which have the potential to address a significant unmet need among patients with various types of tumors. Key investigational therapies include Vidutolimod + nivolumab (Regeneron Pharmaceuticals), LTX-315 (Lytix Biopharma), and AIV001 (AiViva BioPharma), reflecting the diverse strategies being employed to enhance tumor-specific immune responses and improve patient outcomes.<\/p>\n<p style=\"text-align: justify;\">To know more about Intratumoral Cancer Therapies Companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=akpr\">Intratumoral Cancer Therapies Market Access and Reimbursement<\/a><\/p>\n<p style=\"text-align: justify;\">Scope of the Intratumoral Cancer Therapies Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Coverage: 7MM (US, EU4 &ndash; Germany, France, Italy, and Spain &ndash; UK, and Japan)<\/p>\n<\/li>\n<li>\n<p>Study Period: 2020-2034<\/p>\n<\/li>\n<li>\n<p>Forecast Period: 2023-2034<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Companies: Nanobiotix, Replimune, Sirnaomics, OncoSec Medical, Daiichi Sankyo, Amgen, Merck &amp; Co (Viralytics), Moderna Therapeutics, Idera Pharmaceuticals, Philogen, Lokon Pharma, Hookipa Biotech, Vyriad, Intensity Therapeutics, and others.<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies: HENSIFY (NBTXR3), STP705 (cotsiranib), Vidutolimod + nivolumab, LTX-315, AIV001, and others.<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Market Dynamics: current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM market size<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Unmet Needs and Treatment Algorithms<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Table of Contents<\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Key Insights<\/p>\n<\/li>\n<li>\n<p>Report Introduction<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Key Highlights from the Report<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Executive Summary<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Market Forecast Flow<\/p>\n<\/li>\n<li>\n<p>Background and Overview<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Key Endpoints in Intratumoral Cancer Therapies<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Marketed Therapies<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Emerging Therapies<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies: 7 Major Market Analysis<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Market Access and Reimbursement<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies KOL Views<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies SWOT Analysis<\/p>\n<\/li>\n<li>\n<p>Intratumoral Cancer Therapies Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ol>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Abhishek kumar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=intratumoral-cancer-therapies-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20252034-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/sample-request\/intratumoral-cancer-therapies-market-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/intratumoral-cancer-therapies-market-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=intratumoral-cancer-therapies-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20252034-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Intratumoral Cancer Therapies Companies in the market include \u2013 Nanobiotix, Replimune, Sirnaomics, OncoSec Medical, Daiichi Sankyo, Amgen, Merck &#038; Co (Viralytics), Moderna Therapeutics, Idera Pharmaceuticals, Philogen, Lokon Pharma, Hookipa Biotech, Vyriad, Intensity Therapeutics, and others. (Albany, US), October &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/intratumoral-cancer-therapies-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-20252034-delveinsight_842628.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,410,417,412,406],"tags":[],"class_list":["post-842628","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Manufacturing-Industry","category-Marketing-Sales","category-News-Current-Affairs","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/842628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=842628"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/842628\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=842628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=842628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=842628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}